PROLOR Biotech

Company Overview

Snapshot

Founded in January 2005, PROLOR Biotech operates with 11–50 employees. The company was acquired by OPKO Health in August 2013, marking a significant milestone in its journey.

Business overview

PROLOR Biotech specializes in developing proprietary, longer-acting versions of existing therapeutic proteins and peptide drugs, such as human growth hormone. The company's core technology aims to reduce the frequency of administration for treatments, for example, from daily to weekly injections. It primarily focuses on therapies for growth hormone deficiency, hemophilia, and type 2 diabetes, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals & Diagnostics.

Strategic signal

In April 2014, OPKO Health transformed PROLOR Biotech into its Israeli R&D and investment arm. This strategic move indicates OPKO's intent to leverage PROLOR's expertise and infrastructure for future research and development initiatives within the region, signaling a continued focus on innovation and strategic investments in the life sciences sector.

Company Intelligence Q&A

What is PROLOR Biotech's primary focus?

PROLOR Biotech develops proprietary, longer-acting versions of existing therapeutic proteins and peptide drugs to reduce administration frequency for conditions like growth hormone deficiency, hemophilia, and type 2 diabetes.

When was PROLOR Biotech acquired?

PROLOR Biotech was acquired by OPKO Health in August 2013.

What was the strategic outcome of the acquisition by OPKO Health?

In April 2014, OPKO Health integrated PROLOR Biotech as its Israeli R&D and investment arm, indicating a strategic move to utilize PROLOR's capabilities for future research and development.

When did PROLOR Biotech go public?

PROLOR Biotech was listed on the NYSE Amex in March 2010.

What is the current status of PROLOR Biotech?

PROLOR Biotech is currently inactive, having been delisted from AMEX in June 2018 following its acquisition by OPKO Health.